{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:29:12Z","timestamp":1782174552309,"version":"3.54.5"},"reference-count":59,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Most patients with advanced\/metastatic hormone receptor-positive, HER2-negative breast cancer receive first-line therapy with cycline-dependent kinase 4\/6 inhibitors plus endocrine therapy. Almost universally, these patients eventually progress due to the emergence of resistant cancer clones. Targeting the PIK3CA\/AKT1\/PTEN pathway is a way of overcoming resistance. Recently, the oral, selective AKT kinase inhibitor capivasertib has been approved for the treatment of estrogen receptor-positive\/human HER2-growth factor receptor-2 advanced BC with alterations in PIK3CA\/AKT1\/PTEN, in combination with fulvestrant after progression on endocrine therapy. We performed a narrative review to recapitulate the available evidence about capivasertib in the management of advanced hormone receptor-positive, HER2-negative breast cancer, focusing on studies that address preclinical rationale, pharmacology, and clinically relevant problems.<\/jats:p>","DOI":"10.3390\/curroncol33040198","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T13:23:17Z","timestamp":1774963397000},"page":"198","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Carcinoma: A Practical Narrative Review"],"prefix":"10.3390","volume":"33","author":[{"given":"Maria Rosaria","family":"Valerio","sequence":"first","affiliation":[{"name":"Medical Oncology Unit, Policlinico, University of Palermo, 90100 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3909-9833","authenticated-orcid":false,"given":"Daniela","family":"Sambataro","sequence":"additional","affiliation":[{"name":"Medical Oncology, Ospedale Umberto I, 94100 Enna, Italy"},{"name":"Medical Oncology, University of Enna Kore, 94100 Enna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5062-2914","authenticated-orcid":false,"given":"Federica","family":"Martorana","sequence":"additional","affiliation":[{"name":"Medical Oncology, University of Catania, 95121 Catania, Italy"},{"name":"Medical Oncology Unit, Humanitas Istituto Clinico Catanese, 95945 Misterbianco, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Greco","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Policlinico, University of Palermo, 90100 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4445-3288","authenticated-orcid":false,"given":"Chiara","family":"Mesi","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Policlinico, University of Palermo, 90100 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8406-9416","authenticated-orcid":false,"given":"Vittorio","family":"Gebbia","sequence":"additional","affiliation":[{"name":"Medical Oncology, University of Enna Kore, 94100 Enna, Italy"},{"name":"Medical Oncology Unit, CdC Torina, 90100 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5943-6066","authenticated-orcid":false,"given":"Paolo","family":"Vigneri","sequence":"additional","affiliation":[{"name":"Medical Oncology, University of Catania, 95121 Catania, Italy"},{"name":"Medical Oncology Unit, Humanitas Istituto Clinico Catanese, 95945 Misterbianco, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8025-581X","authenticated-orcid":false,"given":"Giuseppa","family":"Scandurra","sequence":"additional","affiliation":[{"name":"Medical Oncology, University of Enna Kore, 94100 Enna, Italy"},{"name":"Medical Oncology Unit, Ospedale Cannizzaro, 95126 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s40265-020-01394-w","article-title":"Targeting the PI3K\/AKT\/mTOR Pathway in Hormone-Positive Breast Cancer","volume":"80","author":"Nunnery","year":"2020","journal-title":"Drugs"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"104485","DOI":"10.1016\/j.breast.2025.104485","article-title":"Expert consensus on treating HR+\/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists","volume":"82","author":"Rugo","year":"2025","journal-title":"Breast"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"17588359251358947","DOI":"10.1177\/17588359251358947","article-title":"Capivasertib\/Fulvestrant in patients with HR+, HER2-low or HER2-negative locally advanced or metastatic breast cancer","volume":"17","author":"Aboud","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"16779","DOI":"10.1007\/s00210-025-04297-3","article-title":"PI3 K\/AKT\/mTOR pathway and its role in breast cancer stem cells","volume":"398","author":"Prabhu","year":"2025","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"17588359251353623","DOI":"10.1177\/17588359251353623","article-title":"Un-derstanding and overcoming CDK4\/6 inhibitor resistance in HR+\/HER2- metastatic breast cancer: Clinical and molecular perspectives","volume":"17","author":"Oliveira","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Liu, L., Graff, S.L., and Wang, Y. (2024). New Emerging Therapies Targeting PI3K\/AKT\/mTOR\/PTEN Pathway in Hormonal Receptor-Positive and HER2-Negative Breast Cancer\u2014Current State and Molecular Pathology Perspective. Cancers, 17.","DOI":"10.3390\/cancers17010016"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Peng, Y., Mei, W., Ma, K., and Zeng, C. (2021). Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.763790"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Alves, C.L., and Ditzel, H.J. (2023). Drugging the PI3K\/AKT\/mTOR Pathway in ER+ Breast Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054522"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/S1470-2045(23)00676-9","article-title":"Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer","volume":"25","author":"Browne","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_10","unstructured":"European Medicines Agency (2025, January 03). Truqap\u00ae Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/truqap-epar-product-information_en.pdf."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"104404","DOI":"10.1016\/j.critrevonc.2024.104404","article-title":"Navigating the complexity of PI3K\/AKT pathway in HER-2 negative breast cancer: Biomarkers and beyond","volume":"200","author":"Sirico","year":"2024","journal-title":"Crit. Rev. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"104488","DOI":"10.1016\/j.breast.2025.104488","article-title":"Advancing breast cancer therapy in the era of molecular diagnostics","volume":"82","author":"Carnevale","year":"2025","journal-title":"Breast"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.breast.2022.03.018","article-title":"\u201cThe emerging role of capivasertib in breast cancer\u201d","volume":"63","author":"Andrikopoulou","year":"2022","journal-title":"Breast"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1200\/JCO.24.00248","article-title":"Endocrine and Targeted Therapy for Hormone Receptor\u2013Positive, Human Epidermal Growth Factor Receptor 2\u2013Negative Metastatic Breast Cancer\u2014Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update","volume":"42","author":"Burstein","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"103997","DOI":"10.1016\/j.esmoop.2024.103997","article-title":"Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)\/protein kinase B (AKT)\/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive\/human epidermal growth factor receptor 2 (HER2)-negative (HR+\/HER2\u2212) advanced breast cancer","volume":"9","author":"Fanucci","year":"2024","journal-title":"ESMO Open"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1158\/1078-0432.CCR-19-3324","article-title":"Genetic Alterations in the PI3K\/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts","volume":"26","author":"Palafox","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1158\/1535-7163.MCT-15-0143","article-title":"AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo","volume":"14","author":"Ribas","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40265-024-01998-6","article-title":"Capivasertib: First Approval","volume":"84","author":"Shirley","year":"2024","journal-title":"Drugs"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1200\/JCO.24.00427","article-title":"US Food and Drug Administration Approval Summary: Capivasertib with Fulvestrant for Hormone Receptor\u2013Positive, Human Epidermal Growth Factor Receptor 2\u2013Negative Locally Advanced or Metastatic Breast Cancer with PIK3CA\/AKT1\/PTEN Alterations","volume":"42","author":"Dilawari","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1177\/10600280241241531","article-title":"Capivasertib: A Novel AKT Inhibitor Approved for Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast Cancer","volume":"58","author":"Luboff","year":"2024","journal-title":"Ann. Pharmacother."},{"key":"ref_21","unstructured":"(2021, December 08). DrugBank. Available online: https:\/\/go.drugbank.com\/."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Zhang, J., Liu, X., Du, Y., Mu, Y., Meng, Y., Sun, Y., Zhang, L., Chen, C., Cullberg, M., and Fan, E. (2025). A Phase I open-label study to assess the pharmacokinetics, safety, and tolerability of capivasertib alone or in combination with paclitaxel in Chinese patients with advanced solid tumors. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-14982-4"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00280-018-3558-z","article-title":"A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK","volume":"81","author":"Dean","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/cpdd.1307","article-title":"Pharmacokinetics of the Akt Serine\/Threonine Protein Kinase Inhibitor, Capivasertib, Administered to Healthy Volunteers in the Presence and Absence of the CYP3A4 Inhibitor Itraconazole","volume":"12","author":"Miller","year":"2023","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e70286","DOI":"10.1111\/cts.70286","article-title":"Population Pharmacokinetics and Exposure-Response Analyses for Capivasertib in Combination With Fulvestrant in Patients With Breast Cancer","volume":"18","author":"Teruel","year":"2025","journal-title":"Clin. Transl. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1158\/1078-0432.CCR-17-2260","article-title":"A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and inPIK3CA-Mutated Breast and Gynecologic Cancers","volume":"24","author":"Banerji","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2017.73.0143","article-title":"AKT Inhibition in Solid Tumors With AKT1 Mutations","volume":"35","author":"Hyman","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1001\/jamaoncol.2020.6741","article-title":"Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial","volume":"7","author":"Kalinsky","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1158\/1078-0432.CCR-19-3953","article-title":"Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer","volume":"26","author":"Smyth","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/bcp.15006","article-title":"Concentration-QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations","volume":"88","author":"Voronova","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1470-2045(19)30817-4","article-title":"Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): A multicentre, randomised, controlled, phase 2 trial","volume":"21","author":"Jones","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S1470-2045(22)00284-4","article-title":"Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): Overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial","volume":"23","author":"Howell","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in Hormone Receptor\u2013Positive Advanced Breast Cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S1470-2045(24)00373-5","article-title":"Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): Patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"25","author":"Oliveira","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12282-024-01640-z","article-title":"Capivasertib and fulvestrant for patients with HR-positive\/HER2-negative advanced breast cancer: Analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial","volume":"32","author":"Tokunaga","year":"2024","journal-title":"Breast Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1038\/s41467-025-59210-6","article-title":"Capivasertib plus fulvestrant in patients with HR-positive\/HER2-negative advanced breast cancer: Phase 3 CAPItello-291 study extended Chinese cohort","volume":"16","author":"Hu","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e13101","DOI":"10.1200\/JCO.2025.43.16_suppl.e13101","article-title":"Single center study of efficacy and safety of capivasertib in hormone receptor\u2013positive (HR+), HER2-negative metastatic breast cancer (MBC)","volume":"43","author":"Joshi","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Hofher, M., and Clifton, K. (2025). Abstract P1-04-15: Real-World Analysis of Safety and Efficacy of Metastatic Breast Cancer Patients Receiving Capivasertib. Clin. Cancer Res., 31.","DOI":"10.1158\/1557-3265.SABCS24-P1-04-15"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"104937","DOI":"10.1016\/j.esmoop.2025.104937","article-title":"366P Efficacy and safety of capivasertib in HR+\/HER2- advanced breast cancer: A systematic review and meta-analysis","volume":"10","author":"Khelifa","year":"2025","journal-title":"ESMO Open"},{"key":"ref_40","first-page":"r762","article-title":"NICE recommends \u201ctargeted\u201d drug capivasertib for advanced breast cancer","volume":"389","year":"2025","journal-title":"BMJ"},{"key":"ref_41","unstructured":"(2026, February 20). Truqap|European Medicines Agency (EMA). Available online: www.ema.europa.eu."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"103697","DOI":"10.1016\/j.esmoop.2024.103697","article-title":"Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: Characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study","volume":"9","author":"Rugo","year":"2024","journal-title":"ESMO Open"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41523-025-00864-2","article-title":"Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive\/HER2-negative advanced breast cancer: Expert opinion","volume":"12","author":"Iyengar","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s13340-025-00841-x","article-title":"Dynamic changes of blood glucose level during capivasertib treatment in metastatic breast cancer: A case report","volume":"16","author":"Sasada","year":"2025","journal-title":"Diabetol. Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"zxaf312","DOI":"10.1093\/ajhp\/zxaf312","article-title":"Capivasertib-induced diabetic ketoacidosis in a patient with stage IV breast cancer: A case report","volume":"15","author":"Mueller","year":"2025","journal-title":"Am. J. Health Pharm."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1080\/14796694.2024.2390791","article-title":"A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer","volume":"20","author":"Turner","year":"2024","journal-title":"Futur. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1016\/j.prro.2025.04.004","article-title":"Radiation Recall Dermatitis Following Capivasertib Administration","volume":"15","author":"Shi","year":"2025","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/annonc\/mdz086","article-title":"BEECH: A dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population","volume":"30","author":"Turner","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_49","first-page":"S0923-7534(25)06332-X","article-title":"Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial","volume":"19","author":"Schmid","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"106049","DOI":"10.1016\/j.esmoop.2025.106049","article-title":"Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: Results from SERENA-1","volume":"11","author":"Vaklavas","year":"2026","journal-title":"ESMO Open"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"201087","DOI":"10.1016\/j.omton.2025.201087","article-title":"Akt inhibition enhances the antitumor efficacy of immune checkpoint blockades and radiotherapy in a syngeneic breast cancer model","volume":"33","author":"Park","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41523-023-00571-w","article-title":"Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models","volume":"9","author":"Hopcroft","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1158\/2767-9764.CRC-24-0113","article-title":"mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors","volume":"4","author":"Sobsey","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41523-025-00752-9","article-title":"The interplay between FOXO3 and FOXM1 influences sensitivity to AKT inhibition in PIK3CA and PIK3CA\/PTEN altered estrogen receptor positive breast cancer","volume":"11","author":"Cutano","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Lang, Y., Chai, Q., Lin, Y., Wu, B., and Liu, X. (2025). Adding capivasertib to fulvestrant in patients with hormone receptor-positive advanced breast cancer: A cost-effectiveness analysis. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1495082"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40273-024-01456-x","article-title":"Cost-Effectiveness of Capivasertib as a Second-Line Therapy for Advanced Breast Cancer","volume":"43","author":"Nguyen","year":"2024","journal-title":"PharmacoEconomics"},{"key":"ref_57","first-page":"900","article-title":"Capivasertib cost-effectiveness in treating advanced breast cancer: A US health care perspective","volume":"31","author":"Okeke","year":"2025","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Martorana, F., Motta, G., Pavone, G., Motta, L., Stella, S., Vitale, S.R., Manzella, L., and Vigneri, P. (2021). AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.662232"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"103334","DOI":"10.1016\/j.critrevonc.2021.103334","article-title":"PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance","volume":"162","author":"Vitale","year":"2021","journal-title":"Crit. Rev. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/4\/198\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T14:05:19Z","timestamp":1774965919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/4\/198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":59,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["curroncol33040198"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33040198","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]}}}